Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov;5(6):933-46.
doi: 10.2217/rme.10.72.

Mesenchymal stem cells for the treatment of neurodegenerative disease

Affiliations
Review

Mesenchymal stem cells for the treatment of neurodegenerative disease

Nanette Joyce et al. Regen Med. 2010 Nov.

Abstract

Mesenchymal stem cells/marrow stromal cells (MSCs) present a promising tool for cell therapy, and are currently being tested in US FDA-approved clinical trials for myocardial infarction, stroke, meniscus injury, limb ischemia, graft-versus-host disease and autoimmune disorders. They have been extensively tested and proven effective in preclinical studies for these and many other disorders. There is currently a great deal of interest in the use of MSCs to treat neurodegenerative diseases, in particular for those that are fatal and difficult to treat, such as Huntington's disease and amyotrophic lateral sclerosis. Proposed regenerative approaches to neurological diseases using MSCs include cell therapies in which cells are delivered via intracerebral or intrathecal injection. Upon transplantation into the brain, MSCs promote endogenous neuronal growth, decrease apoptosis, reduce levels of free radicals, encourage synaptic connection from damaged neurons and regulate inflammation, primarily through paracrine actions. MSCs transplanted into the brain have been demonstrated to promote functional recovery by producing trophic factors that induce survival and regeneration of host neurons. Therapies will capitalize on the innate trophic support from MSCs or on augmented growth factor support, such as delivering brain-derived neurotrophic factor or glial-derived neurotrophic factor into the brain to support injured neurons, using genetically engineered MSCs as the delivery vehicles. Clinical trials for MSC injection into the CNS to treat traumatic brain injury and stroke are currently ongoing. The current data in support of applying MSC-based cellular therapies to the treatment of neurodegenerative disorders are discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Mesenchymal stem cell-mediated neurotrophic factor secretion to promote neuritogenesis and synaptic connection between damaged neurons
(A) Damaged neurons ‘round-up’ and retract axons, this prevents effective signaling between cells in the neural network. (B) Mesenchymal stem cells can promote axon extension to restore synaptic connections between neurons by secreting neurotrophic factors. Additional benefits from mesenchymal stem cells in the brain tissue are reduction in inflammation at sites of damage, increased vascularization, reduction of levels of free radicals and a local reduction in apoptosis of damaged cells.

Similar articles

Cited by

References

Bibliography

    1. Williams JT, Southerland SS, Souza J, et al. Cells isolated from adult human skeletal muscle capable of differentiating into multiple mesodermal phenotypes. Am Surg. 1999;65:22–26. - PubMed
    1. Galmiche MC, Koteliansky VE, Briere J, et al. Stromal cells from human long-term marrow cultures are mesenchymal cells that differentiate following a vascular smooth muscle differentiation pathway. Blood. 1993;82:66–76. - PubMed
    1. Theise ND, Nimmakayalu M, Gardner R, et al. Liver from bone marrow in humans. Hepatology. 2000;32:11–16. - PubMed
    1. Theise ND, Badve S, Saxena R, et al. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology. 2000;31:235–240. - PubMed
    1. Petersen BE, Bowen WC, Patrene KD, et al. Bone marrow as a potential source of hepatic oval cells. Science. 1999;284:1168–1170. - PubMed

Websites

    1. Karussis D. ClinicalTrials.gov. A service of the US National Institutes of Health; 2010. multiple sclerosis AND stem cell. http://clinicaltrials.gov/ct2/show/NCT00781872.
    1. ClinicalTrials.gov. A service of the US National Institutes of Health multiple sclerosis AND stem cell. Jun 1, 2010. http://clinicaltrials.gov/ct2/results?term=mesenchymal+stem+cells+multip...
    1. Clinical Trials http://clinicaltrials.gov

Publication types

MeSH terms

Substances